{"id":64142,"date":"2026-04-28T13:06:39","date_gmt":"2026-04-28T05:06:39","guid":{"rendered":"https:\/\/flcube.com\/?p=64142"},"modified":"2026-04-28T13:06:40","modified_gmt":"2026-04-28T05:06:40","slug":"jecho-biopharmaceuticals-secures-fda-clearance-for-jlm019-clinical-study-in-advanced-malignant-tumors-novel-bispecific-fc-fusion-protein-targets-cold-tumors","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=64142","title":{"rendered":"Jecho Biopharmaceuticals Secures FDA Clearance for JLM019 Clinical Study in Advanced Malignant Tumors \u2013 Novel Bispecific Fc Fusion Protein Targets &#8220;Cold Tumors&#8221;"},"content":{"rendered":"\n<p><strong>Jecho Biopharmaceuticals Co., Ltd.<\/strong>, a China-based joint venture between <strong>U.S.-based Jecho Laboratories, Inc.<\/strong> and <strong>France-headquartered Sartorius Stedim Biotech&#8217;s China unit<\/strong>, announced it has received clearance from the <strong>U.S. Food and Drug Administration (FDA)<\/strong> to initiate a clinical study of <strong>JLM019<\/strong> for the treatment of <strong>advanced malignant tumors<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestones\">Regulatory Milestones<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Jurisdiction<\/th><th>Status<\/th><th>Timeline<\/th><th>Indication<\/th><\/tr><\/thead><tbody><tr><td><strong>United States<\/strong><\/td><td>FDA clearance granted<\/td><td>April 2026<\/td><td>Advanced malignant tumors<\/td><\/tr><tr><td><strong>China<\/strong><\/td><td>Clinical approval obtained<\/td><td>August 2025<\/td><td>Advanced malignant tumors<\/td><\/tr><tr><td><strong>Development Stage<\/strong><\/td><td>First-in-human clinical trials<\/td><td>Q2 2026 expected<\/td><td>Global development program<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism-of-action\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Compound<\/strong>: JLM019, bispecific Fc fusion protein<\/li>\n\n\n\n<li><strong>Targets<\/strong>: Simultaneously binds <strong>CD80<\/strong> and <strong>PD-1<\/strong><\/li>\n\n\n\n<li><strong>Dual Mechanism<\/strong>:<\/li>\n\n\n\n<li><strong>Relieves Inhibition<\/strong>: Blocks PD-1 ligand-mediated immunosuppressive signals<\/li>\n\n\n\n<li><strong>Activates Immunity<\/strong>: Utilizes CD80 to provide potent co-stimulatory signals to T cells<\/li>\n\n\n\n<li><strong>Innovation<\/strong>: First-in-class approach combining checkpoint inhibition with co-stimulation in single molecule<\/li>\n\n\n\n<li><strong>Therapeutic Focus<\/strong>: Designed specifically for <strong>&#8220;cold tumors&#8221;<\/strong> \u2013 immunologically non-responsive malignancies<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-preclinical-evidence-amp-therapeutic-rationale\">Preclinical Evidence &amp; Therapeutic Rationale<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Aspect<\/th><th>Finding<\/th><th>Significance<\/th><\/tr><\/thead><tbody><tr><td><strong>Preclinical Efficacy<\/strong><\/td><td>Demonstrated preliminary efficacy in tumor models<\/td><td>Proof-of-concept for dual modulation approach<\/td><\/tr><tr><td><strong>Target Population<\/strong><\/td><td>&#8220;Cold tumors&#8221; with limited response to current immunotherapies<\/td><td>Addresses significant unmet medical need<\/td><\/tr><tr><td><strong>Mechanistic Advantage<\/strong><\/td><td>Simultaneous inhibition relief + T cell activation<\/td><td>Potential to convert immunologically &#8220;cold&#8221; tumors to &#8220;hot&#8221;<\/td><\/tr><tr><td><strong>Development Strategy<\/strong><\/td><td>Dual regulatory pathway (US + China)<\/td><td>Accelerated global development timeline<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-partnership-structure\">Strategic Partnership Structure<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-joint-venture-composition\">Joint Venture Composition<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Jecho Laboratories, Inc.<\/strong> (U.S.): Drug discovery and development expertise<\/li>\n\n\n\n<li><strong>Sartorius Stedim Biotech China<\/strong> (France): Bioprocessing and manufacturing capabilities<\/li>\n\n\n\n<li><strong>Jecho Biopharmaceuticals<\/strong> (China): Integrated development and commercial entity<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-competitive-advantages\">Competitive Advantages<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Global Development<\/strong>: Simultaneous US and China clinical programs<\/li>\n\n\n\n<li><strong>Manufacturing Integration<\/strong>: Access to Sartorius&#8217;s bioprocessing expertise<\/li>\n\n\n\n<li><strong>Market Access<\/strong>: Dual-continent regulatory strategy<\/li>\n\n\n\n<li><strong>Resource Optimization<\/strong>: Leveraged capabilities across partners<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-amp-clinical-need\">Market Opportunity &amp; Clinical Need<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>&#8220;Cold Tumor&#8221; Challenge<\/strong>: Majority of solid tumors are immunologically &#8220;cold&#8221; and resistant to current checkpoint inhibitors<\/li>\n\n\n\n<li><strong>Treatment Gap<\/strong>: Limited options for patients who fail or don&#8217;t respond to existing immunotherapies<\/li>\n\n\n\n<li><strong>Market Size<\/strong>: Large addressable population across multiple tumor types<\/li>\n\n\n\n<li><strong>First-Mover Potential<\/strong>: Novel mechanism could establish new treatment paradigm<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-outlook\">Development Outlook<\/h2>\n\n\n\n<p>The FDA clearance represents a critical milestone for Jecho Biopharmaceuticals&#8217; transition from preclinical to clinical development. The dual regulatory strategy\u2014having already secured Chinese clinical approval in August 2025\u2014positions JLM019 for accelerated global development and potential simultaneous market access in the world&#8217;s two largest pharmaceutical markets.<\/p>\n\n\n\n<p>The bispecific Fc fusion protein&#8217;s unique mechanism of simultaneously blocking immunosuppression while providing co-stimulation addresses a fundamental limitation of current immunotherapies, potentially offering hope to patients with currently untreatable &#8220;cold&#8221; tumor phenotypes.<\/p>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory approvals, clinical development, and therapeutic potential. Actual outcomes may differ due to risks including clinical trial results, regulatory decisions, and competitive developments.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Jecho Biopharmaceuticals Co., Ltd., a China-based joint venture between U.S.-based Jecho Laboratories, Inc. and France-headquartered&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[62,4718,2503],"class_list":["post-64142","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-jecho-biopharmaceuticals","tag-sartorius"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Jecho Biopharmaceuticals Secures FDA Clearance for JLM019 Clinical Study in Advanced Malignant Tumors \u2013 Novel Bispecific Fc Fusion Protein Targets &quot;Cold Tumors&quot; - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Jecho Biopharmaceuticals Co., Ltd., a China-based joint venture between U.S.-based Jecho Laboratories, Inc. and France-headquartered Sartorius Stedim Biotech&#039;s China unit, announced it has received clearance from the U.S. Food and Drug Administration (FDA) to initiate a clinical study of JLM019 for the treatment of advanced malignant tumors.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=64142\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Jecho Biopharmaceuticals Secures FDA Clearance for JLM019 Clinical Study in Advanced Malignant Tumors \u2013 Novel Bispecific Fc Fusion Protein Targets &quot;Cold Tumors&quot;\" \/>\n<meta property=\"og:description\" content=\"Jecho Biopharmaceuticals Co., Ltd., a China-based joint venture between U.S.-based Jecho Laboratories, Inc. and France-headquartered Sartorius Stedim Biotech&#039;s China unit, announced it has received clearance from the U.S. Food and Drug Administration (FDA) to initiate a clinical study of JLM019 for the treatment of advanced malignant tumors.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=64142\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-28T05:06:39+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-28T05:06:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64142#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64142\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Jecho Biopharmaceuticals Secures FDA Clearance for JLM019 Clinical Study in Advanced Malignant Tumors \u2013 Novel Bispecific Fc Fusion Protein Targets &#8220;Cold Tumors&#8221;\",\"datePublished\":\"2026-04-28T05:06:39+00:00\",\"dateModified\":\"2026-04-28T05:06:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64142\"},\"wordCount\":461,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"Jecho Biopharmaceuticals\",\"Sartorius\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64142#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64142\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=64142\",\"name\":\"Jecho Biopharmaceuticals Secures FDA Clearance for JLM019 Clinical Study in Advanced Malignant Tumors \u2013 Novel Bispecific Fc Fusion Protein Targets \\\"Cold Tumors\\\" - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-28T05:06:39+00:00\",\"dateModified\":\"2026-04-28T05:06:40+00:00\",\"description\":\"Jecho Biopharmaceuticals Co., Ltd., a China-based joint venture between U.S.-based Jecho Laboratories, Inc. and France-headquartered Sartorius Stedim Biotech's China unit, announced it has received clearance from the U.S. Food and Drug Administration (FDA) to initiate a clinical study of JLM019 for the treatment of advanced malignant tumors.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64142#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64142\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64142#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Jecho Biopharmaceuticals Secures FDA Clearance for JLM019 Clinical Study in Advanced Malignant Tumors \u2013 Novel Bispecific Fc Fusion Protein Targets &#8220;Cold Tumors&#8221;\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Jecho Biopharmaceuticals Secures FDA Clearance for JLM019 Clinical Study in Advanced Malignant Tumors \u2013 Novel Bispecific Fc Fusion Protein Targets \"Cold Tumors\" - Insight, China&#039;s Pharmaceutical Industry","description":"Jecho Biopharmaceuticals Co., Ltd., a China-based joint venture between U.S.-based Jecho Laboratories, Inc. and France-headquartered Sartorius Stedim Biotech's China unit, announced it has received clearance from the U.S. Food and Drug Administration (FDA) to initiate a clinical study of JLM019 for the treatment of advanced malignant tumors.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=64142","og_locale":"en_US","og_type":"article","og_title":"Jecho Biopharmaceuticals Secures FDA Clearance for JLM019 Clinical Study in Advanced Malignant Tumors \u2013 Novel Bispecific Fc Fusion Protein Targets \"Cold Tumors\"","og_description":"Jecho Biopharmaceuticals Co., Ltd., a China-based joint venture between U.S.-based Jecho Laboratories, Inc. and France-headquartered Sartorius Stedim Biotech's China unit, announced it has received clearance from the U.S. Food and Drug Administration (FDA) to initiate a clinical study of JLM019 for the treatment of advanced malignant tumors.","og_url":"https:\/\/flcube.com\/?p=64142","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-28T05:06:39+00:00","article_modified_time":"2026-04-28T05:06:40+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=64142#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=64142"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Jecho Biopharmaceuticals Secures FDA Clearance for JLM019 Clinical Study in Advanced Malignant Tumors \u2013 Novel Bispecific Fc Fusion Protein Targets &#8220;Cold Tumors&#8221;","datePublished":"2026-04-28T05:06:39+00:00","dateModified":"2026-04-28T05:06:40+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=64142"},"wordCount":461,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial approval \/ initiation","Jecho Biopharmaceuticals","Sartorius"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=64142#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=64142","url":"https:\/\/flcube.com\/?p=64142","name":"Jecho Biopharmaceuticals Secures FDA Clearance for JLM019 Clinical Study in Advanced Malignant Tumors \u2013 Novel Bispecific Fc Fusion Protein Targets \"Cold Tumors\" - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-28T05:06:39+00:00","dateModified":"2026-04-28T05:06:40+00:00","description":"Jecho Biopharmaceuticals Co., Ltd., a China-based joint venture between U.S.-based Jecho Laboratories, Inc. and France-headquartered Sartorius Stedim Biotech's China unit, announced it has received clearance from the U.S. Food and Drug Administration (FDA) to initiate a clinical study of JLM019 for the treatment of advanced malignant tumors.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=64142#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=64142"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=64142#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Jecho Biopharmaceuticals Secures FDA Clearance for JLM019 Clinical Study in Advanced Malignant Tumors \u2013 Novel Bispecific Fc Fusion Protein Targets &#8220;Cold Tumors&#8221;"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64142","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=64142"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64142\/revisions"}],"predecessor-version":[{"id":64143,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64142\/revisions\/64143"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=64142"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=64142"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=64142"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}